Background Large pragmatic clinical trials (PCTs) are increasingly used to conduct comparative effectiveness research. In the context of planning a safety PCT of the live herpes zoster vaccine in rheumatoid arthritis (RA) patients aged 50 years receiving anti-tumor necrosis factor (TNF) therapy, we evaluated the use of health plan combined with registry data to assess the feasibility of recruiting the 4000 patients needed for the trial and to facilitate site selection. Methods Using national US data from Medicare, we identified older RA patients who received anti-TNF therapy in the last quarter of 2009. Extrapolations were made from the Medicare patient population to younger patients and those with other types of insurance using the Consortium of Rheumatology Researchers of North America (CORRONA) disease registry. Patients' treating rheumatologists were grouped into practices and sorted by size from the greatest to the least number of eligible patients. Results Approximately 50,000 RA patients receiving anti-TNF therapy were identified in the Medicare data, distributed across 1980 physician practices. After augmenting Medicare data with information from CORRONA and extrapolating to younger patients and those with other types of insurance, more than 12,000 potentially eligible study subjects were identified from the 50 largest rheumatology practices. Conclusion Health plan and registry databases appear useful to assess feasibility of large pragmatic trials and to assist in selection of recruitment sites with the greatest number of potentially eligible patients. This novel approach is applicable to trials with simple inclusion/exclusion criteria that can be readily assessed in these data sources. Clinical Trials 2014; 11: 96-101. http://ctj.sagepub.com
Background
The increasing importance of comparative effectiveness research (CER) continues to spotlight a need to develop and refine the methods that are used to generate new, real-world evidence [1] . Randomized controlled trials and, specifically, large pragmatic to the target population, and PCTs examine hard outcomes that allow for simplified data collection for clinically relevant endpoints [3] [4] [5] [6] . PCTs can be challenging to execute due to the large number of patients required. Failure to recruit patients as expected can have a major impact on the science and budget of CER studies.
The National Institutes of Health (NIH) and other sponsors typically require a multistage process in order to consider funding a RCT or PCT that begins with a planning grant. Among the activities required at this stage of trial design is specification of a detailed approach to patient recruitment and site selection in order to demonstrate feasibility. Accurate estimates of numbers of eligible patients and associated recruitment site selection are essential. However, efficient methods are needed to provide assurance that adequate numbers of patients can be recruited and to know which physician office practice settings have the greatest number of potentially eligible patients in order to select recruitment sites.
In the context of planning a PCT to evaluate the safety of the live herpes zoster vaccine in older rheumatoid arthritis (RA) patients receiving anti-tumor necrosis factor (TNF) therapy, we used both health plan and registry data to (1) assess the feasibility of recruiting the 4000 patients expected to be needed for the trial based upon key inclusion criteria and (2) to facilitate investigator site selection. This report describes our assessment methods as an example of a highly generalizable framework that might be used in planning future trials for a variety of rheumatic diseases and other chronic medical conditions.
Methods

Inclusion criteria of the example trial
The proposed Varicella zostER VaccinE (VERVE) trial is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity, and long-term effectiveness of the live herpes zoster vaccine among patients aged 50 years or older currently receiving anti-TNF therapy for RA or other inflammatory arthritis. Anti-TNF therapy improves clinical signs and symptoms of RA and reduces X-ray damage and associated disability. However, because of the potential risk that patients treated with these biologic therapies are immunosuppressed, a live virus vaccine, therefore, poses a theoretical risk that it could trigger zoster reactivation [7] .This restriction is not based upon clinical data and thus prompted the interest in a safety trial of the vaccine in this population. A total of 4000 patients are required to attain 80% power to demonstrate noninferiority of the clinical safety of the vaccine compared to placebo. As with most trials, there are expected costs related to initiating each trial site to cover Institutional Review Board (IRB) fees, site training, and data monitoring. For the VERVE trial, an additional site-related cost will be the deployment of tablet computers used to facilitate efficient patient identification, the consent process, and data collection. Therefore, minimizing the number of recruitment sites is preferred. Moreover, because RA is relatively rare and not all US rheumatologists conduct research, the feasibility of screening and enrolling the required number of patients needed to be demonstrated.
Health plan used to assess feasibility
As one example of a large healthcare database, we used the 2009 Medicare data of 100% of beneficiaries with inflammatory autoimmune diseases with traditional fee-for-service Medicare. Medicare data is made available to the public for qualified research purposes by the Center for Medicare and Medicaid Services (CMS) and is subject to privacy restrictions defined as part of a Data Use Agreement. Medicare administrative data includes monthly coverage indicators for all enrollees and encompasses inpatient and outpatient claims, prescriptions filled under Medicare Part D, and information on all Medicare providers. We identified enrollees who were aged 60 years with RA. A person was defined to have RA if they had at least two office visits claims with RA diagnosis codes (ICD9-CM 714.X) [8] [9] [10] . Because VERVE requires patients to be currently receiving anti-TNF therapy, we restricted patients to those who filled a prescription for, or received an infusion of, any anti-TNF agent (adalimumab, certolizumab, etanercept, golimumab, and infliximab) in the last calendar quarter of 2009 identified from Part B (infusion/injection) or Part D (prescriptions filled). These patients were linked to treating rheumatologists through use of National Provider Identification (NPI) numbers and the physician specialty field available in the Medicare data for every submitted claim. Rheumatologists were grouped together into practices (offices) using the tax identification numbers used for billing purposes available in the CMS data. We calculated the ratio of the number of eligible patients with fee-for-service Medicare with Part D prescription coverage (Parts A, B, and D) to the number of patients with any type of Medicare coverage (Part A, Part B, Part D, other type of drug plan, or Medicare Advantage).
Cross-referencing with registry data
Although RA patients younger than 65 years of age might qualify for Medicare on the basis of disability (which is an allowable reason based upon the US Clinical trial feasibility using health plan data 97 Social Security Disability listing of Adult Impairments [11] ), most younger patients were not expected to have Medicare coverage. Therefore, to obtain more information on younger patients (age 50 years) and patients older than 65 years who were not in Medicare, rheumatologists were crossreferenced with the list of physicians participating in the Consortium of Rheumatology Researchers of North America (CORRONA), the largest US rheumatology registry with physician-derived data [12, 13] . CORRONA data are collected in a de-identified fashion. The participating physicians at each site are the only individuals who have access to the protected health information that would be needed to uniquely identify patients. The CORRONA dataset is not publically available, and patient participants provide written informed consent as part of their enrollment in the registry. CORRONA includes 387 physicians covering 39 states, with high generalizability to the RA population in the United States (Curtis et al., American College of Rheumatology 2013, San Diego, CA).
The CORRONA data were searched for eligible patients in a similar fashion as in Medicare. Within the CORRONA data across all participating rheumatology practices, we identified the proportion of eligible patients aged 50 years on anti-TNF therapy at the end of 2009 with Medicare insurance coverage (self-reported by patients at every CORRONA visit) compared to the total number of eligible patients with Medicare or non-Medicare insurance coverage. This reciprocal of this proportion was multiplied by the patient numbers obtained in the Medicare administrative data to estimate the total number of eligible patients in each rheumatologist's practice across all insurance types. For example, if 40% of eligible patients in CORRONA had Medicare insurance coverage, then the estimated number of patients obtained from the Medicare administrative data would be multiplied by (1/0.4) = 2.5.
Finally, we identified physicians currently participating or who had participated in clinical or RA-specific research in the past using publically available sources of information (e.g., investigator list of the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial [14] ; acknowledgements sections of other published rheumatology RCTs listing participating sites; the Food and Drug Administration registry of physicians who conduct clinical research, available since 1992 [15] ).
Statistical analysis
We multiplied the total number of RA patients who had fee-for-service Medicare with prescription drug coverage (Parts A, B, and D) by the cumulative product of the various multipliers to calculate the total number of eligible patients for VERVE. The total number of eligible RA patients was plotted against the number of rheumatologist practices (which could consist of one or more rheumatologists) at which these patients received care. We sorted practices by descending number of eligible patients (e.g., Site 1 has the greatest number of patients). The resulting figure was examined in light of the needed sample size of 4000 eligible patients, varying assumptions about the patient recruitment rate (e.g., 25%, 33% and 50% of all eligible patients). This range of recruitment assumptions were felt to have face validity given the simple nature of the trial that is not burdensome for participants and is minimally intrusive for physicians to conduct; for example, for most participants, only a single-study visit is required.
We conducted a sensitivity analysis based on three key sources of variance in our estimates that might affect the generalizability of our estimates derived using 2009 data to the results we might expect in 2014 when the trial began recruiting. These three parameters included the proportion of Medicare patients who had Medicare Advantage (rather than traditional fee-for-service coverage) or a non-Part D drug plan, changing prevalence of biologic use over time, and variability in the proportion of RA patients with Medicare coverage across CORRONA sites, accounting for practice-level variability.
Finally, we ran a simulation using bootstrap methods with 10,000 iterations to model these three sources of variance. We reported the interquartile range around our primary recruitment estimates based upon the bootstrap result. All analyses were performed using SAS 9.2. Medicare data were governed by a Data Use Agreement with CMS, and the University of Alabama at Birmingham IRB approved the study protocol. CORRONA data were governed by a Data Use Agreement with CORRONA.
Results
A total of 47,623 RA patients identified in the Medicare fee-for-service administrative data met age criteria and received any anti-TNF therapy in the last quarter of 2009. These individuals were assigned to their 3547 treating rheumatologists and the associated 1980 rheumatology practices at which they received care.
Correction factor multipliers
As of 1 January 2009, we estimated that 35.8% of the RA patients in our Medicare data were enrolled in Medicare Advantage plans and/or were not enrolled in a Part D plan, indicating that the raw fee-for-service data available to us represented approximately 64% of the total Medicare patient population (with any type of coverage) who would be eligible for the trial (Table 1 ). This estimate was intentionally conservative given that only approximately 40% of Medicare patients have traditional fee for service with Part D coverage in any given month (data not shown; based upon the Medicare random 5% sample). To extrapolate to the entirety of the Medicare population, we then multiplied the number of eligible patients derived from the raw data for the traditional fee-for-service Medicare enrollees by its reciprocal, yielding a ratio of 1.56.
Overall, 47% of patients aged 50 years and older in CORRONA who met our inclusion criteria had any form of Medicare coverage. Our final multiplier (cumulative product of all multipliers, rounded to two digits after the decimal for display purposes) was 3.29 (Table 1) . After applying the overall ratio to the raw numbers from Medicare fee-for-service data, we, therefore, estimated that 156,263 participants with any type of insurance coverage would potentially be eligible for VERVE (Figure 1 ).
The number of eligible patients identified was plotted for the 100 largest rheumatology practices sorted by the greatest to the least number of potential participants (Figure 1, dashed line) . Almost all of the largest practices had evidence that they had participated in clinical research, as evidenced by this line being almost superimposed with the dotted line for the first 6000 patients. Considering rheumatologists who conduct research (solid line) and with a hypothesized trial participation rate of 33% (which would require 12,000 eligible patients to be screened), 40-45 rheumatology practices would be required to successfully recruit the proposed PCT to yield the needed 4000 patients.
Derivation of estimates used for sensitivity analysis and bootstrap simulation results
Based upon the literature [16] , the proportion of Medicare beneficiaries enrolled in Medicare Advantage has increased over the past several years, but in the evaluation of Medicare Advantage plan enrollment from its inception, there has not been a consistent nor a linear increase over time [17] . Thus, for our sensitivity analysis, we estimated that the eligible traditional fee-for-service Medicare population with Part D drug coverage could increase or decrease by up to 3% compared to 2009 (Table 1) .
Regarding trends in biologic use among RA patients, Zhang et al. [18] found no overall Clinical trial feasibility using health plan data 99 appreciable change in overall biologic use from 2007 to 2009 in the Medicare program. Nevertheless, although we used no change in the prevalence over time for our base case estimates, we allowed that anti-TNF use among RA patients might increase or decrease by 610% by the time VERVE begins recruitment. Finally, we observed appreciable variability across CORRONA sites in the proportion of eligible patients who had Medicare coverage. Based upon the distribution of the proportion of eligible patients at each site who had Medicare coverage, and selecting a sampling distribution from the 10th and 90th percentiles, the interquartile range of the recruitment ratio estimated in our primary results spanned from 2.73 to 3.73. Thus, based upon this result, the trial could potentially need up to 620% fewer or more patients to screen for VERVE compared to the base case estimate (Table 1 ).
Discussion
In the context of planning a large PCT, we used administrative data linked with a disease registry to assess the feasibility of recruiting the necessary number of eligible patients and to facilitate site selection for patient recruitment. We observed that a reasonable number of rheumatology practices (~50) would be required to participate in order to access a sufficiently large pool of potentially eligible patients. Using plausible assumptions about patient participation (e.g., 25%233% of all eligible patients), the trial was considered feasible with regard to attaining the recruitment goal and in light of the trial's resources.
Our novel approach leverages increasingly available data from health plans and insurance systems, as well as information from large registries. While these data are frequently used for CER and other research, acquiring these data from CMS or other sources (e.g., commercial insurance plans or health systems) and obtaining permission to use them are not without cost or administrative burden. Moreover, because our trial needed patients aged 50 years and older, Medicare data alone were suboptimal to provide the complete picture desired to support trial feasibility. Using data from CORRONA, a large US RA registry, to derive estimates of the number of patients with other types of health insurance was, therefore, valuable to improve the estimation of the number of eligible patients available nationwide. Conversely, having only the data from a registry would represent only the sites and patients enrolled and would miss both patients who declined registry participation as well as physicians not participating in the registry. Thus, the data sources are complementary.
The geographic and demographic generalizability of the 100% Medicare data used to identify Medicare enrollees is high. However, we recognize that information for patients enrolled in self-contained managed healthcare systems (e.g., Kaiser Permanente) will not be represented within CMS data. Another potential limitation of our approach to planning some trials by using health plan data relates to a lack of detailed clinical information in these information sources. Only a few administrative data sources contain lab test results (e.g., C-reactive protein). Therefore, this approach of using administrative claims or health plan data is limited to assessing recruitment feasibility where precise phenotypic information is not required. However, since the VERVE trial, like most PCTs, has very simple inclusion criteria, the data sources used were well suited for the needed feasibility assessment. A disease registry like COR-RONA is of even greater value if detailed phenotypic information (e.g., disease activity) is required. Finally, although we used statistical techniques to model variance in our recruitment estimates, they could potentially be incorrect depending on the actual trends over time with respect to insurance coverage and biologic use, thus potentially under-or overestimating the total number of eligible patients available for the VERVE trial. While this may be a limitation for VERVE, the main goal of this report was to showcase how administrative data along with registry data could be used in planning a PCT irrespective of the specific use case; researchers should permute the parameters they feel are most essential to obtain accurate recruitment targets for their particular study.
In conclusion, large health plan databases and registries appear useful to assess the feasibility of large pragmatic trials and to assist in selection of physician offices with the greatest number of eligible patients. This novel approach is applicable to trials with simple inclusion/exclusion criteria that can be readily assessed with these data sources.
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